MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Anika Therapeutics Inc

Closed

SectorHealthcare

10.49 -6.67

Overview

Share price change

24h

Current

Min

10.49

Max

10.96

Key metrics

By Trading Economics

Income

17M

-4.9M

Sales

27M

26M

Profit margin

-18.622

Employees

288

EBITDA

-29M

-2.7M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+91.28% upside

Dividends

By Dow Jones

Next Earnings

30 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-42M

165M

Previous open

17.16

Previous close

10.49

News Sentiment

By Acuity

27%

73%

63 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Anika Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 May 2025, 17:03 UTC

Earnings
Major Market Movers

Anika Therapeutics Shares Fall After Slump in 1Q Pain-Treatment Sales in U.S.

Peer Comparison

Price change

Anika Therapeutics Inc Forecast

Price Target

By TipRanks

91.28% upside

12 Months Forecast

Average 21.5 USD  91.28%

High 24 USD

Low 19 USD

Based on 2 Wall Street analysts offering 12 month price targets forAnika Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

14.51 / 14.745Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

63 / 376 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.